Echo-Screen III Pro - The Echo-Screen III hearing screener is a - NATUS MEDICAL INCORPORATED

Duns Number:962519208

Device Description: The Echo-Screen III hearing screener is a portable, handheld, battery-operated device that The Echo-Screen III hearing screener is a portable, handheld, battery-operated device that can detect hearing loss using Otoacoustic Emission or Auditory Brainstem Response screening technologies. The Echo-Screen III may be configured to support one or any combination of TEOAE, DPOAE, and AABR technologies.

Want to know more about this Product? Request more information now!


More Product Details

Catalog Number

-

Brand Name

Echo-Screen III Pro

Version/Model Number

Echo-Screen III

Device Commercial Distribution Status

In Commercial Distribution

Commercial Distribution End Date

-

Issuing Agency

In GS1

Product Characteristics

MRI safety Status

Labeling does not contain MRI Safety Information

Device required to be labeled as containing natural rubber latex or dry natural rubber (21 CFR 801.437)

-

Device labeled as "Not made with natural rubber latex"

-

For Single-Use

-

Prescription Use (Rx)

-

Over the Counter (OTC)

-

Kit

-

Combination Product

-

Human Cell, Tissue or Cellular or Tissue-Based Product (HCT/P)

-

FDA Premarket Submission

K141446

Product Code Details

Product Code

EWO

Product Code Name

Audiometer

Device Record Status

Public Device Record Key

fb999ac9-7324-44bd-944f-4106fd64396e

Public Version Date

July 06, 2018

Public Version Number

3

DI Record Publish Date

August 25, 2017

Additional Identifiers

Package DI Number

None

Quantity per Package

-

Contains DI Package

-

Package Discontinue Date

-

Package Status

-

Package Type

-

"NATUS MEDICAL INCORPORATED" Characteristics
Device Class Device Class Description No of Devices
1 A medical device with low to moderate risk that requires general controls 24
2 A medical device with a moderate to high risk that requires special controls. 302
3 A medical device with high risk that requires premarket approval 5